Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

Open access
Hadoux, Julien, Favier, Judith, Scoazec, Jean‐Yves, Leboulleux, Sophie, Al Ghuzlan, Abir, Caramella, Caroline, Déandreis, Désirée, Borget, Isabelle, Loriot, Céline, Chougnet, Cécile, Letouzé, Eric, Young, Jacques, Amar, Laurence, Bertherat, Jérome, Libé, Rosella, Dumont, Frédéric, Deschamps, Frédéric, Schlumberger, Martin, Gimenez‐Roqueplo, Anne Paule, Baudin, Eric · 2014 · International Journal of Cancer

Abstract

Cyclophosphamide–dacarbazine–vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours. We investigated the therapeutic benefit of temozolomide (TMZ), an oral alternative to dacarbazine, in patients with MPP. This is a retrospective study of consecutive patients with documented progressive MPP. We examined the correlation between Succinate dehydrogenase B (SDHB) mutation and O(6)‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation and MGMT expression in the French nation‐wide independent cohort of 190 pheochromocytomas or paragangliomas (PP). Progression‐free survival (PFS) according to RECIST 1.1 and PERCIST 1.0 criteria was the primary end point. Fifteen consecutive patients with MPP were enrolled; ten (67%) carried a mutation in SDHB. The mean dose intensity of TMZ was 172 mg/m 2/d for 5 days every 28 days. Median PFS was 13.3 months after a median follow‐up of 35 months. There were five partial responses (33%), seven stable (47%) and three progressive diseases (20%). Grade 3 toxicities were lymphopenia in two patients and hypertension in one. Partial responses were observed only in patients with mutation in SDHB. MGMT immunohistochemistry was negative in tumour samples from four patients who responded to treatment. SDHB germline mutation was associated with hypermethylation of the MGMT promoter and low expression of MGMT in 190 samples of the French nation‐wide independent cohort. This study demonstrates that TMZ is an effective antitumour agent in patients with SDHB‐related MPP. The silencing of MGMT expression as a consequence of MGMT promoter hypermethylation in SDHB‐mutated tumours may explain this finding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.28913

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Hadoux, J., Favier, J., Scoazec, J., Leboulleux, S., Al Ghuzlan, A., Caramella, C., Déandreis, D., Borget, I., Loriot, C., Chougnet, C., Letouzé, E., Young, J., Amar, L., Bertherat, J., Libé, R., Dumont, F., Deschamps, F., Schlumberger, M., Gimenez‐Roqueplo, A. P., & Baudin, E.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2014-05-05
Volume
135
Issue
11
Pages
2711-2720
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W1948768651
Cited by
210
References
2
FWCI
12.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.